Verona Pharma Plc - ADR

Verona Pharma Plc - ADR

VRNA - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$9.16B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Verona Pharma Plc - ADRVerona Pharma Plc - ADR-63.6--29%53.50.9
$35.19

Current Fair Value

67.1% downside

Overvalued by 67.1% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$9.16 Billion
Enterprise Value$8.96 Billion
Earnings per Share$-1.68
Beta0.05
Outstanding Shares85,644,897

Return

Return on Equity-29.18%ROE
Return on Assets-14.17%
Return on Invested Capital-21.24%

Valuation & Multiples

P/E Ratio-63.64P/E Ratio
PEG54.47PEG
Price to Sales53.46Price to Sales
Price to Book Ratio35.64Price to Book Ratio
Enterprise Value to Revenue40.43
Enterprise Value to EBIT-80.88
Enterprise Value to Net Income-111
Total Debt to Enterprise0.03
Debt to Equity0.88Debt to Equity

Revenue Sources

No data

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.70, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.7014▼ 265.45%
Total Calls638,600▼ 29.17%
Total Puts447,912▼ 85.20%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %93.93%▲ 82.75%
Total Invested$8.58B▲ 19.54%
Investors Holding268▼ 46.00%

About Verona Pharma Plc

CEO: David Zaccardelli

Verona Pharma Plc Insider Information FAQ

In the latest 13F quarter on Stockcircle, 8 top investors reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.